World's Best Scientists 2026 revealed!
Bernard Zinman

Bernard Zinman

Award Badge
Medicine
Canada
2023

D-Index & Metrics

Medicine

D-Index
147
Citations
128611
World Ranking
1250
National Ranking
38

Research.com Recognitions

  • 2023 - Research.com Medicine in Canada Leader Award

Overview

Bernard Zinman is affiliated with the University of Toronto in Canada and has contributed extensively to medical research, particularly in the fields of endocrinology, diabetes, and metabolism. Their work primarily focuses on diabetes treatment and management, with notable attention to pancreatic function, chronic kidney disease related to diabetes, and broader metabolism studies involving diabetes and cancer.

Their research spans a range of topics including:

  • Diabetes Treatment and Management
  • Pancreatic function and diabetes
  • Diabetes Management and Research
  • Metabolism, Diabetes, and Cancer
  • Gestational Diabetes Research and Management
  • Chronic Kidney Disease and Diabetes
  • Diet and metabolism studies

Zinman has published a significant number of articles in leading journals related to diabetes and metabolism. Frequent publication venues include:

  • Diabetes Obesity and Metabolism (21 publications)
  • Diabetes (17 publications)
  • Diabetes Care (16 publications)
  • UNC Libraries (10 publications)
  • Circulation (6 publications)

Key recent papers authored or co-authored by Zinman include:

  • Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER, 2021, published in Circulation
  • Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial, 2020, published in The Lancet Diabetes & Endocrinology
  • Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial, 2020, published in Kidney International
  • Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial, 2020, published in Journal of the American Society of Nephrology
  • Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers, 2022, published in Alzheimer's & Dementia Translational Research & Clinical Interventions

Their collaboration network includes frequent co-authors such as:

  • Christoph Wanner
  • Silvio E. Inzucchi
  • Jyothis T. George
  • Michaela Mattheus
  • David Fitchett

Zinman's research contributions are concentrated in the subfields of endocrinology, diabetes and metabolism, surgery, molecular biology, obstetrics and gynecology, and nephrology. The counts of publications across these subfields are considerable, showing a diverse research portfolio.

This profile reflects the work of a scientist deeply engaged in investigating complex interrelations between diabetes, kidney function, and metabolic disorders, often through clinical trials and large-scale analyses.

Best Publications

  • Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

    Bernard Zinman;Christoph Wanner;John M. Lachin;David Fitchett

  • Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

    David M. Nathan;Patricia A. Cleary;Jye Yu C Backlund;Saul M. Genuth

  • Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes

    David M. Nathan;John B. Buse;Mayer B. Davidson;Ele Ferrannini

  • Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

    Vlado Perkovic;Vlado Perkovic;Meg J. Jardine;Meg J. Jardine;Bruce Neal;Bruce Neal;Bruce Neal;Severine Bompoint

  • Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

    Kahn Se;Haffner Sm;Heise Ma;Herman Wh

  • International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes

    David M. Nathan;Beverly Balkau;Enzo Bonora;Knut Borch-Johnsen

  • Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals

    Hertzel C. Gerstein;Johannes F. E. Mann;Qilong Yi;Bernard Zinman

  • Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

    rosiglitazone Medication Trial Investigators;H C Gerstein;S Yusuf

  • Impaired fasting glucose and impaired glucose tolerance: implications for care.

    David M. Nathan;Mayer B. Davidson;Ralph A. DeFronzo;Robert J. Heine

  • Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

    Rury R. Holman;M. Angelyn Bethel;Robert J. Mentz;Vivian P. Thompson

  • [Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. (A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes)].

    D M Nathan;J В Buse;M В Davidson;R J Heine

  • Diabetic Retinopathy and Diabetic Macular Edema: Pathophysiology, screening, and novel therapies

    Thomas A. Ciulla;Armando G. Amador;Bernard Zinman

  • Liraglutide and Renal Outcomes in Type 2 Diabetes

    Johannes F.E. Mann;David D. Ørsted;Kirstine Brown-Frandsen;Steven P. Marso

  • Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.

    Julio Rosenstock;Vlado Perkovic;Odd Erik Johansen;Mark E. Cooper

  • Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial

    David Fitchett;Bernard Zinman;Bernard Zinman;Christoph Wanner;John M. Lachin

  • Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

    D. M. Nathan;J. B. Buse;M. B. Davidson;E. Ferrannini

  • Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

    Bernard Zinman;John E. Gerich;John B. Buse;Andrew Lewin

  • Renal and Retinal Effects of Enalapril and Losartan in Type 1 Diabetes

    Michael Mauer;Bernard Zinman;Robert Gardiner;Samy Suissa

  • Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association.

    Sarah D. de Ferranti;Ian H. de Boer;Vivian Fonseca;Caroline S. Fox

  • Are Metabolically Healthy Overweight and Obesity Benign Conditions

    Caroline K. Kramer;Bernard Zinman;Ravi Retnakaran

Frequent Co-Authors

Anthony J.G. Hanley
Anthony J.G. Hanley University of Toronto
Philip W. Connelly
Philip W. Connelly University of Toronto
Stewart B. Harris
Stewart B. Harris University of Western Ontario
Robert A. Hegele
Robert A. Hegele University of Western Ontario
Christoph Wanner
Christoph Wanner University of Würzburg
Silvio E. Inzucchi
Silvio E. Inzucchi Yale University
John M. Lachin
John M. Lachin George Washington University
Subodh Verma
Subodh Verma University of Toronto
Steven E. Kahn
Steven E. Kahn University of Washington
John B. Buse
John B. Buse University of North Carolina at Chapel Hill

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Beyond traditional medical degrees, online programs offer flexible options for advancing your career in healthcare. For those seeking leadership roles in hospitals or healthcare organizations, consider online mha programs cahme accredited. These programs ensure high standards and open doors to management opportunities.

Registered nurses looking to upgrade their qualifications without extensive hands-on requirements may benefit from rn to bsn online programs without clinicals. Such pathways make it easier to fit studies around busy work schedules.

If rapid advancement is a priority, you can explore shortest dnp programs online designed to speed up your journey toward the highest levels of clinical practice or healthcare leadership—with completion times often under two years.

For cost-conscious professionals, researching the cheapest dnp program lets you enhance your credentials without a massive investment. Online pathways continue to evolve, offering a broad array of career opportunities within and beyond patient care.

Best Scientists Citing Bernard Zinman

Trending Scientists

Recently Published Articles